Boehringer Ingelheim Vetmedica Gmbh

Other

Boehringer Ingelheim International Gmbh

Boehringer International Gmbh

Boehringer Ingelheim Animal Health USA Inc.

Knut Elbers

Vicky Fachinger

Marion Kixmoeller

Axel Lischewski

Francois-Xavier Orveillon

Isabelle Freiin Von Richthofen

Martina Von Freyburg

Michael Dennis Piontkowski

Gregor Meyers

Marika Christine Genzow

Nikolaus Osterrieder

Carola Kissel

Luc-Etienne Fabry

Isabelle Von Richthofen

Christian Seyboldt

Johannes Geser

Bernd Zierenberg

Joachim Eicher

Stefan Henke

William Charles Ohnesorge

Gerald Behrens

Kathleen Kwan Young Park

Ricarda Deitmer

Francois Xavier Orveillon

Ralph Christian Reimholz

Dirk Neven Rauleder

Christiane Fetzer

Wiliam Charles Ohnesorge

Kathleen Park

Christiane Meyer

Jeffrey P Knittel

Craig Jones

Gregor Tremblay

Isabelle Frein Von Richthofen

The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.

Treatment of pigs with PCV2 antigen

A method for preparing a vaccine for immunization against the disease PorcineDisease and/or Enzootic Pneumonia in pigs in which a first container is only partly filled with a first vaccine and a second container is filled with a second vaccine, the second vaccine being transferred into the first container through an adapter device, when a closure device is penetrated for the first and/or only time, and the vaccinating agent is prepared therein, thus making the operation simple, less error-prone and more hygienic, while reducing the materials required.

Method for the preparation of a vaccinating agent

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.

Treatment of PRDC in pigs

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs.

Prevention and treatment of sub-clinical PCVD

The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and() antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) andassociated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by, or a method for reduction of clinical symptoms caused by or associated with a PCV2 andinfection, comprising the step of administering an effective amount of PCV2 antigen andantigen to an animal in need of such treatment.

[object Object]

Prophylaxis and treatment of PRDC

A kit, a method of using it and a process for preparing a vaccine for immunization against the disease Porcine Circovirus Disease and/or Enzootic Pneumonia in pigs are proposed, in which a first container is only partly filled with a first vaccine and a second container is filled with a second vaccine, the second vaccine being transferred into the first container through an adapter device, when a closure device is penetrated for the first and/or only time, and the vaccinating agent is prepared therein, thus making the operation simple, less error-prone and more hygienic, while reducing the materials required. The adapter device has a pair of oppositely facing piercing elements formed of one of needles, hollow, spikes, wedges with at least one through passage extending through both piercing elements, each of the containers being pierced by a respective one of the piercing elements creating a fluid connection between the containers.

Kit for the preparation of a vaccinating agent

The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen.

Reduction of concomitant infections in pigs by the use of PCV2 antigen

The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by, comprising: an immunizing amount of abacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection byfor at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.

One dose vaccination against mycoplasma infections of pigs

Treatment of pigs with PCV2 antigent

Growing community of inventors

Mittelbiberach, Germany

Knut Elbers